Artemis Investment Management LLP Has $93.19 Million Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Artemis Investment Management LLP raised its stake by 133.4% in Q4, adding 49,555 shares to hold 86,716 shares of Eli Lilly worth $93.19 million, about 1.1% of Artemis’s portfolio and its 26th largest position.
• Eli Lilly reported strong Q1 results (EPS $8.55 vs. $6.97 estimate; revenue $19.8B, +55.5% YoY) and set FY2026 guidance of $35.50–$37.00 EPS, driven by momentum in its GLP‑1 franchise.
• While many analysts have raised price targets and ratings, near‑term risks include FDA liver‑safety reports for oral GLP‑1 Foundayo and competitive/price pressure from Novo Nordisk that could weigh on uptake and margins.

Artemis Investment Management LLP raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 133.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 86,716 shares of the company's stock after acquiring an additional 49,555 shares during the quarter. Eli Lilly and Company comprises approximately 1.1% of Artemis Investment Management LLP's holdings, making the stock its 26th largest position. Artemis Investment Management LLP's holdings in Eli Lilly and Company were worth $93,192,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Maryland Capital Advisors Inc. acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Miller Global Investments LLC acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $33,000. Dorato Capital Management acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $36,000. New England Capital Financial Advisors LLC lifted its stake in Eli Lilly and Company by 142.9% in the fourth quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company's stock valued at $37,000 after acquiring an additional 20 shares during the last quarter. Finally, Vermillion & White Wealth Management Group LLC lifted its stake in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock valued at $27,000 after acquiring an additional 16 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong fundamentals: Q1 results and revenue beat underscore momentum in GLP‑1 franchise (Mounjaro/Foundayo) and underpin raised guidance. Eli Lilly Stock (LLY) Opinions on Q1 Earnings and Foundayo Safety Report
• Positive Sentiment: Foundayo commercial launch is off to a fast start — broad pharmacy access and payer coverage are driving new prescribers and patient uptake, supporting near‑term sales growth for Lilly. Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
• Positive Sentiment: Durable clinical readthrough: New long‑term data show Omvoh (mirikizumab) maintained disease clearance in ulcerative colitis at four years — a meaningful validation for Lilly’s immunology portfolio and future revenue stability. Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
• Positive Sentiment: Wall Street backing: Multiple firms have raised price targets and reiterated outperform/buy ratings (examples include Barclays and Wolfe Research), which supports investor sentiment and provides upside catalysts. Barclays/Wolfe coverage and price target updates
• Neutral Sentiment: Dividend: Lilly declared a $1.73 quarterly dividend (payable June 10), a modest yield that is shareholder‑friendly but not a major valuation driver. Lilly declares second-quarter 2026 dividend
• Negative Sentiment: Safety headwind: The FDA has logged serious liver events in patients taking Foundayo, which sparked a short‑term share dip and ongoing safety monitoring risk that could slow uptake or trigger label/payer scrutiny. FDA Reports Liver Failure in Patient Taking Lilly's Foundayo
• Negative Sentiment: Competitive/pricing pressure: Novo Nordisk’s oral pill momentum and talk of a price war raise margin and market‑share risk for all GLP‑1 players, keeping pricing dynamics a key watch item for Lilly. Novo Nordisk Faces Price War as Weight-Loss Pill Demand Rises

Analysts Set New Price Targets

A number of research firms have issued reports on LLY. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an "overweight" rating in a research note on Thursday, February 5th. Guggenheim reissued a "buy" rating and issued a $1,183.00 price target on shares of Eli Lilly and Company in a research report on Tuesday. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $1,285.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 6th. Sanford C. Bernstein reissued an "outperform" rating on shares of Eli Lilly and Company in a research report on Tuesday, March 10th. Finally, Freedom Capital raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,217.59.

Eli Lilly and Company Trading Up 2.2%

NYSE:LLY opened at $989.02 on Wednesday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company's 50 day moving average is $946.66 and its 200-day moving average is $988.51. The firm has a market cap of $931.40 billion, a price-to-earnings ratio of 35.13, a P/E/G ratio of 1.07 and a beta of 0.48. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter in the previous year, the firm posted $3.34 earnings per share. Eli Lilly and Company's revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 35.39 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company's payout ratio is 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.